Reviews/Osteoporosis Fracture Prevention/Romosozumab cardiovascular risk
Anabolic And Sequential Therapy · ostfrac_09 · v2
The question is whether romosozumab raises the risk of heart attacks, strokes and related cardiovascular events. Most of the real-world studies that compared romosozumab against other osteoporosis drugs found no higher risk, and several actually found lower risk estimates. The one study pointing clearly toward harm [1] simply counts how often cardiovascular events were reported to a safety database, which can flag a possible signal but cannot prove the drug causes the events, and most of those reports came from Japan. The panel also noted that regulators warn against giving the drug to high-risk heart patients, so doctors may already be steering such patients away, which could hide a real risk in the comparison studies. Because the large comparative studies did not show an increase, the evidence does not support the claim, but the lingering safety signal and that possible steering effect stop the panel from ruling it out entirely.
The largest comparative cohort [2] found no difference in major adverse cardiovascular events between romosozumab and teriparatide, aHR 1.00 (0.94-1.06), including in patients with prior MACE. A multicentre cohort versus denosumab [4] reported a non-significant aHR of 1.42 (0.64 to 3.19) for one-year MACE and 1.05 (0.62 to 1.78) for all cardiovascular adverse events. A nationwide claims study [11] found all hazard ratios below 1.0 versus PTH analogues, denosumab and bisphosphonates, and a CKD target-trial emulation [15] reported lower MACE (HR 0.82, 0.70-0.97) and myocardial infarction (HR 0.77, 0.63-0.95). The sole direct positive is a FAERS disproportionality analysis [1] detecting an elevated MACE signal (ROR 4.07, 2.39-6.93), driven primarily by Japanese reports. The contested point: The evidence divides between the pharmacovigilance signal [1] and the predominantly null-to-favourable comparative cohorts [2][4][11][15]. The panel split on whether those null cohorts are genuine reassurance or are biased toward the null by channeling of high-cardiovascular-risk patients away from romosozumab under regulatory warnings.
All 17 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The null real-world comparative results are confounded toward the null by channeling: regulatory black-box warnings steer high-CV-risk patients away from romosozumab, so active-comparator cohorts [2][4][11][15] systematically underestimate true risk and are weak evidence against the claim.
The only direct positive evidence [1] is a FAERS disproportionality analysis — subject to reporting bias, dominated by Japanese reports, and incapable of establishing causation or incidence; it cannot carry the claim on its own.
Where it remains uncertain. The null cohorts [2][4][11][15] may be confounded toward the null by channeling high-risk patients away from the drug, while the pivotal randomised outcome trial that generated the original signal is absent from the corpus.
Aleatory
In [4] cardiovascular events are few, producing wide confidence intervals (one-year MACE aHR 0.64 to 3.19) that leave chance variation unable to be separated from a true effect.
Epistemic
The pivotal placebo- or active-controlled randomised cardiovascular-outcome report is absent; it survives only as excluded secondary news summaries [7][8], so the strongest causal evidence is unavailable.
The load-bearing papers from a corpus of 17, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only direct positive signal; disproportionality, hypothesis-generating, not incidence.
“Elevated reports for MACE (ROR 4.07, 95% CI: 2.39-6.93) was identified overall, which was primarily driven by the significant disproportionality measures in the Japanese reports.”
Panel auditInternal validity: low · scope of inference: Reporting pattern for MACE among romosozumab adverse-event reports, not a measured risk in a defined treated population.Key limitations: disproportionality not risk · reporting bias · signal concentrated in Japan · no denominator
Largest comparative cohort shows no increase in MACE risk.
“The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94-1.06).”
Panel auditInternal validity: medium · scope of inference: MACE risk of romosozumab relative to teriparatide in Japanese patients aged 40+ initiating either drug.Key limitations: active comparator not placebo · residual confounding · claims-data outcome ascertainment · Japan-specific
Independent real-world cohort; numerically higher MACE but non-significant (aHR 1.42, 0.64-3.19).
“romosozumab use was not associated with a statistically significant increase in cardiovascular risk compared with denosumab.”
Panel auditInternal validity: medium · scope of inference: Real-world MACE and CVAE risk of romosozumab versus denosumab in Korean patients aged 50+.Key limitations: underpowered wide CIs · active comparator · observational · single-country three hospitals
Large nationwide registry; all HRs <1.0 vs multiple comparators.
“After adjustment for baseline characteristics, no excess incidence of cardiovascular events was observed among patients receiving Rmab compared with those receiving other AOMs.”
Panel auditInternal validity: medium · scope of inference: Cardiovascular incidence of romosozumab versus other anti-osteoporosis drugs in Japanese patients 50+ without prior MI/stroke.Key limitations: high-CV-risk patients excluded · active comparators · channeling away from CV-history patients · Japan-specific
4 of 17 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Predominantly null comparative evidence fails to confirm an increase, but a persistent disproportionality signal plus channeling confounding prevent refutation, so the claim of an increase is Doubtful rather than refuted.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Absent randomised cardiovascular-outcome trial. The corpus contains no primary randomised report of the signal that generated the regulatory warnings, leaving the strongest causal evidence missing. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Obtain and score the primary ARCH-type placebo- or active-controlled randomised trial reporting adjudicated cardiovascular events.
Open question: Does romosozumab increase adjudicated cardiovascular events relative to placebo? Why it is still open: Every included comparison uses an active comparator [2][4][11][15] and the randomised placebo-controlled outcome data are absent, present only as excluded summaries [7][8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19